UREMOL HC CREAM

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

UREA; HYDROCORTISONE ACETATE

Beschikbaar vanaf:

GLAXOSMITHKLINE INC

ATC-code:

D07XA01

INN (Algemene Internationale Benaming):

HYDROCORTISONE

Dosering:

10%; 1%

farmaceutische vorm:

CREAM

Samenstelling:

UREA 10%; HYDROCORTISONE ACETATE 1%

Toedieningsweg:

TOPICAL

Eenheden in pakket:

5G/50G/225G

Prescription-type:

Prescription

Therapeutisch gebied:

ANTI-INFLAMMATORY AGENTS

Product samenvatting:

Active ingredient group (AIG) number: 0231440001; AHFS:

Autorisatie-status:

CANCELLED POST MARKET

Autorisatie datum:

2014-06-23

Productkenmerken

_2014-04-15/131-pristine-english-Uremol.doc _
_ _
_ _
_ _
_Page 1 of 22 _
PRESCRIBING INFORMATION
PR
UREMOL
® HC
Hydrocortisone acetate USP 1% (w/w)
and Urea USP 10% (w/w) Cream
Hydrocortisone acetate USP 1% (w/v)
and Urea USP 10% (w/v) Lotion
TOPICAL CORTICOSTEROID – EMOLLIENT
GlaxoSmithKline Inc.
Date of Revision:
7333 Mississauga Road
April 16, 2014
Mississauga, Ontario
L5N 6L4
www.stiefel.ca
Control Number: 170409
_©_
_2014 GlaxoSmithKline Inc., All Rights Reserved _
_®_
_UREMOL is a registered trademark, used under license by
GlaxoSmithKline Inc. _
_2014-04-15/131-pristine-english-Uremol.doc _
_ _
_ _
_ _
_Page 2 of 22 _
TABLE OF CONTENTS
PAGE
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................................
9
DRUG INTERACTIONS
.........................................................................................................................
9
DOSAGE AND ADMINISTRATION
...................................................................................................
10
OVERDOSAGE
.....................................................................................................................................
11
ACTION AND CLINICAL
PHARMACOLOGY..................................................................................
11
STORAGE AND STABILITY
......................................